Royalty Pharma PLC is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.
Royalty Pharma PLC is a leading buyer of pharmaceutical royalties and a global pioneer in the field of royalty investments. The company acquires existing royalty interests in approved biopharmaceutical products and provides capital to pharmaceutical companies in exchange for a portion of future royalty revenues, allowing it to participate in the long-term success of innovative therapies.
(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)
Royalty Pharma PLC is a net-positive Humankind Value company. This outcome is largely driven by the company’s contributions to Healthcare R&D ($20.7 B), Pharmaceuticals ($1.6 B), and Economic Value ($904.8 M). The value associated with Healthcare R&D and Pharmaceuticals is linked to an estimate of 430,000 additional years lived by people worldwide. The Humankind Value of this company could improve with reductions in Biofuel Production (-$313.5 M) and Greenhouse Gases (-$93.2 M). Healthcare R&D, Pharmaceuticals, Economic Value, and Greenhouse Gases are attached to this company through its direct business activities. Biofuel Production is mostly or entirely a result of supply-chain relationships.